West Pharmaceutical Services, Inc. (NYSE:WST) Stock Has Average Price Target of $382.00 According to Brokerages

Shares of West Pharmaceutical Services, Inc. (NYSE:WST) have been given an average recommendation of “Moderate Buy” by the fourteen analysts that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $382.00.

WST has been the subject of several research reports. Stephens reissued an “overweight” rating and issued a $360.00 target price on shares of West Pharmaceutical Services in a report on Tuesday, June 2nd. KeyCorp raised their price target on West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “overweight” rating in a research note on Thursday, July 2nd. Citigroup lifted their price target on West Pharmaceutical Services from $400.00 to $412.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. BNP Paribas Exane began coverage on West Pharmaceutical Services in a report on Monday, July 13th. They issued an “outperform” rating and a $447.00 price objective for the company. Finally, Barclays upgraded shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $310.00 to $400.00 in a research report on Tuesday, June 9th.

Insider Transactions at West Pharmaceutical Services

In other West Pharmaceutical Services news, VP Annette Favorite sold 8,135 shares of West Pharmaceutical Services stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $340.81, for a total value of $2,772,489.35. Following the transaction, the vice president directly owned 16,845 shares in the company, valued at approximately $5,740,944.45. The trade was a 32.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders have sold 15,659 shares of company stock worth $5,443,749. Company insiders own 0.60% of the company’s stock.

Hedge Funds Weigh In On West Pharmaceutical Services

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in West Pharmaceutical Services during the 2nd quarter worth approximately $2,387,990,000. State Street Corp increased its holdings in shares of West Pharmaceutical Services by 1.7% in the second quarter. State Street Corp now owns 3,348,698 shares of the medical instruments supplier’s stock valued at $1,202,183,000 after purchasing an additional 54,920 shares during the period. Artisan Partners Limited Partnership raised its stake in shares of West Pharmaceutical Services by 2.9% during the fourth quarter. Artisan Partners Limited Partnership now owns 2,850,401 shares of the medical instruments supplier’s stock worth $784,259,000 after purchasing an additional 79,481 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of West Pharmaceutical Services during the second quarter worth approximately $733,733,000. Finally, Generation Investment Management LLP acquired a new stake in shares of West Pharmaceutical Services during the second quarter worth $728,168,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Up 0.4%

Shares of NYSE:WST opened at $377.18 on Friday. The firm has a 50 day simple moving average of $351.03 and a 200-day simple moving average of $321.02. West Pharmaceutical Services has a twelve month low of $223.83 and a twelve month high of $386.00. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $26.55 billion, a PE ratio of 48.29, a P/E/G ratio of 2.63 and a beta of 1.14.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, topping the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The firm had revenue of $872.30 million for the quarter, compared to analyst estimates of $839.98 million. During the same period last year, the business earned $1.84 EPS. West Pharmaceutical Services’s revenue for the quarter was up 13.8% compared to the same quarter last year. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, equities analysts predict that West Pharmaceutical Services will post 8.93 EPS for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were given a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 0.2%. The ex-dividend date of this dividend was Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 11.27%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global manufacturer of components and systems used in the packaging and delivery of injectable drugs and other healthcare products. The company serves pharmaceutical, biotechnology and medical device manufacturers.

Its products include elastomer closures, syringe and cartridge components, vial seals, administration systems, drug-delivery components and other specialized packaging solutions. West also provides contract-manufacturing services for certain medical and pharmaceutical products.

Founded in 1923, West Pharmaceutical Services supplies customers through manufacturing and operations in North America, Europe and Asia.